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Over the past decade it has become clear that sensible,
safe, evidence-based guidelines are required for the follow-
up of cancer patients. Patient expectations for high-quality
care have increased, although ever-increasing restrictions
are being imposed on expensive health care resources.
Therefore the need for constructive, cost-effective, high-
quality guidelines for patients with a range of cancer types
has now become urgent.
For patients who have had a melanoma frequent clinical
consultation and regular imaging studies are still common
practice in many centres, despite a lack of evidence
regarding their influence on overall survival, disease-free
survival or quality of life.1,2 Why is this so? In the first
place we cling to historical precedent. It is well known that
this form of cancer is unpredictable, and the assumption
has therefore been made that it should be monitored fre-
quently and carefully. Secondly, it seems appropriate to
detect recurrence at an early stage, since effective treat-
ment of local, in-transit and regional node metastases offers
the possibility of cure, and long-term survival can also
follow complete resection of systemic metastases. Third,
patient satisfaction and patient reassurance are provided by
frequent clinical consultation.
In this and a recent issue of Annals of Surgical Oncology
two interesting studies are reported.3,4 The study of Meyer
et al. is a retrospective report of 118 American Joint
Committee on Cancer (AJCC) stage II and III melanoma
patients who underwent regular structural imaging with
a minimum follow-up of 2 years. Recurrence occurred
in 35% (n = 43), of which 43% (n = 15) were distant
metastases. However, only 7% (n = 3) of these patients
were asymptomatic and had their recurrence detected by
routine imaging. Another 26% (n = 11) were detected
by routine clinical follow-up, including medical history
and physical examination.1,5,6 This study is consistent
with previous reports that found two-thirds of melanoma
recurrences were patient detected.
The study of Morton et al. evaluated 108 patients with
AJCC stage IIIA and IIIB melanoma who were prospec-
tively enrolled in a monitoring schedule of 6-monthly chest
X-rays (CXR) in addition to clinical follow-up. They found
metastases in 21% (n = 23) of the patients, which were
detected in 48% (n = 11) by surveillance CXR. The other
pulmonary metastases were not detected by CXR surveil-
lance. The authors found sensitivity and specificity for
surveillance CXR was 48% [95% confidence interval (CI)
0.27–0.68] and 78% (95%CI 0.77–0.79), respectively. In
only 13% (n = 3) was metastasectomy considered appro-
priate. Moreover, 19 patients had a false-positive result for
melanoma metastasis, 10 of whom underwent a pulmonary
biopsy. This study confirms earlier results of retrospective
studies: routine CXR does not seem to contribute to an
improvement in survival of melanoma patients, nor is it
cost effective.7–9
The results of these two valuable studies underscore
the limited value of routine imaging in the follow-up of
melanoma patients. However, both studies have their
shortcomings. First the retrospective nature by the study
of Meyer et al. and the lack of a control group in the study
by Morton et al. reduce the level of evidence according to
standard methodology. Second, the low number of patients
in both studies makes them underpowered due to the low
rate of events. Nevertheless, this type of clinical report is
of great importance since large-scale prospective studies
and appropriately designed randomised studies are extre-
mely difficult to perform in this particular field; they
might even be a waste of time and money based on
current knowledge.
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On the other hand, it is important to recognise that
evidence documenting the value of clinical follow-up in
melanoma patients is still inadequate and that prospective
studies are required to determine which format will offer
best care not only in terms of survival but also in quality of
life. Most patients prefer frequent follow-up consultations
and imaging studies to detect early recurrent disease.
However, frequent visits and imaging studies such as
conventional X-rays, spiral computed tomography (CT)
scans and positron emission tomography (PET) scans do
not seem to alter their outcome. Therefore, it might be
more worthwhile to focus on different aspects of follow-up.
It becomes increasingly obvious that follow-up schedules
should be much more patient tailored. Several current
national guidelines for melanoma management fail to
clearly differentiate between patients with various AJCC/
International Union against Cancer (UICC) stages of mel-
anoma disease when recommending follow-up protocols,
although it has been shown that the risk of recurrence
ranges widely according to disease stage.10,11 In relation to
this, the current opportunity for accurate nodal staging
afforded by sentinel node biopsy is extremely valuable,
regardless of its potential survival benefit. The excellent
prognosis of patients who are sentinel node negative means
that intensive follow-up is probably not required, while
those found to be sentinel node positive have a much
greater risk of recurrence and may therefore warrant more
intensive follow-up. A further point to be considered is
that, to improve patient satisfaction regarding follow-up,
new guidelines should take into account patient charac-
teristics such as such as age, accessibility to health care and
level of anxiety. The melanoma specialist should have the
opportunity to have flexibility in the interpretation of new
guidelines, so that a follow-up schedule can be recom-
mended to fit the individual patient. Finally, education of
patients is likely to be the most important aspect of follow-
up and should be completely integrated in the follow-up
program. Several recent studies have shown that the
detection of recurrence is most commonly by patients and
their partners, rather than by doctors at routine follow-up
visits.5,7,12–14 The current melanoma follow-up study
(MELFO), being undertaken in The Netherlands seeks to
determine whether improved patient education and reduced
follow-up is a safe and cost-effective approach to mela-
noma follow-up.14
OPEN ACCESS This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
REFERENCES
1. Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients
with localised primary cutaneous melanoma. Lancet Oncol.
2005;6:608–21.
2. Nieweg OE, Kroon BB. The conundrum of follow-up: should it
be abandoned? Surg Oncol Clin N Am 2006;15:319–30.
3. Meyers MO, Yeh JJ, Frank J, Long P, Deal AM, Amos KD, et al.
Method of detection of initial recurrence of stage II/III cutaneous
melanoma: analysis of utility of follow-up staging. Ann Surg
Oncol. 2008. doi:10.1245/s10434-008-0238-y
4. Morton RL, Craig JC, Thompson JF. The role of surveillance
chest x-rays in the follow-up of high-risk melanoma patients. Ann
Surg Oncol. 2008. doi:10.1245/s10434-008-0207-5
5. Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ,
Thompson JF. Detection of first relapse in cutaneous melanoma
patients: implications for the formulation of evidence-based fol-
low-up guidelines. Ann Surg Oncol. 2007;14:1924–33.
6. Francken AB, Thompson JF, Bastiaannet E, Hoekstra HJ.
[Detection of the first recurrence in patients with melanoma: three
quarters by the patient, one quarter during outpatient follow-up].
Ned Tijdschr Geneeskd. 2008;152:557–62.
7. Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D.
Primary staging and follow-up in melanoma patients—mono-
center evaluation of methods, costs and patient survival. Br J
Cancer. 2002;87:151–7.
8. Tsao H, Feldman M, Fullerton JE, Sober AJ, Rosenthal D,
Goggins W. Early detection of asymptomatic pulmonary mela-
noma metastases by routine chest radiographs is not associated
with improved survival. Arch Dermatol. 2004;140:67–70.
9. Mooney MM, Mettlin C, Michalek AM, Petrelli NJ, Kraybill
WG. Life-long screening of patients with intermediate-thickness
cutaneous melanoma for asymptomatic pulmonary recurrences: a
cost-effectiveness analysis. Cancer. 1997;80:1052–64.
10. Francken AB, Accortt NA, Shaw HM, Colman MH, Wiener M,
Soong SJ, et al. Follow-up schedules after treatment for malig-
nant melanoma. Br J Surg. 2008;95:1401–7.
11. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS,
Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma
patients: validation of the American Joint Committee on Cancer
melanoma staging system. J Clin Oncol. 2001;19:3622–34.
12. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P,
O’Fallon JR. Utility of follow-up tests for detecting recurrent
disease in patients with malignant melanomas. JAMA.
1995;274:1703–5.
13. Baughan CA, Hall VL, Leppard BJ, Perkins PJ. Follow-up in
stage I cutaneous malignant melanoma: an audit. Clin Oncol (R
Coll Radiol) 1993;5:174–80.
14. Francken AB, Bastiaannet E, Hoekstra-Weebers JEHM,
Schaapveld M, Hoekstra HJ. MELFO: prospective randomized
trial for the evaluation of a theoretical follow-up schedule in
cutaneous melanoma patients; 2006. http://www.ikcnet.nl/trials.
Accessed 18 November 2008.
Follow-Up of Melanoma Patients: The Need for Evidence-Based Protocols 805
